peginterferon alfa-2b 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	5164	215647-85-1

Description:

Molecule	Description
Synonyms: peginterferon alfa-2b pegintron	A covalent conjugate of recombinant interferon alpha, subtype 2b, and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha-2b protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha-2b, thereby extending the duration of its therapeutic effects, but may also reduce the interferon-mediated stimulation of an immune response Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

peginterferon alfa-2b
pegintron

A covalent conjugate of recombinant interferon alpha, subtype 2b, and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha-2b protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha-2b, thereby extending the duration of its therapeutic effects, but may also reduce the interferon-mediated stimulation of an immune response

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
7.50	mcg	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Jan. 19, 2001	FDA	SCHERING

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Platelet count decreased	455.06	34.31	180	2886	115942	63370014
Anaemia	432.98	34.31	230	2836	293200	63192756
White blood cell count decreased	228.95	34.31	118	2948	138986	63346970
Neutrophil count decreased	177.24	34.31	75	2991	56331	63429625
Blood bilirubin increased	152.96	34.31	60	3006	37080	63448876
Haemoglobin decreased	122.50	34.31	80	2986	145405	63340551
No adverse event	119.84	34.31	52	3014	41353	63444603
Product quality issue	106.90	34.31	46	3020	35819	63450137
Pyrexia	89.09	34.31	111	2955	470367	63015589
Hepatitis C	50.54	34.31	16	3050	5258	63480698
Decreased appetite	48.45	34.31	60	3006	250992	63234964
Hepatocellular carcinoma	44.89	34.31	12	3054	2182	63483774
Exposure via father	43.32	34.31	8	3058	264	63485692
Malaise	39.16	34.31	71	2995	415883	63070073

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaemia	293.45	30.99	215	3241	233120	34720355
Platelet count decreased	279.69	30.99	163	3293	119554	34833921
White blood cell count decreased	188.70	30.99	117	3339	95328	34858147
Product quality issue	156.56	30.99	60	3396	16975	34936500
Hepatocellular carcinoma	132.54	30.99	43	3413	7466	34946009
Neutrophil count decreased	109.20	30.99	66	3390	51038	34902437
Blood bilirubin increased	96.35	30.99	55	3401	38241	34915234
Pyrexia	81.45	30.99	129	3327	332884	34620591
No adverse event	80.19	30.99	41	3415	22886	34930589
Haemoglobin decreased	79.08	30.99	77	3379	120695	34832780
Influenza like illness	64.95	30.99	38	3418	27596	34925879
Hyperbilirubinaemia	44.47	30.99	25	3431	16818	34936657
Rash	36.89	30.99	73	3383	222679	34730796
Treatment failure	32.75	30.99	31	3425	46666	34906809

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Platelet count decreased	741.58	28.48	339	5808	194325	79543916
Anaemia	696.89	28.48	427	5720	444588	79293653
White blood cell count decreased	426.63	28.48	231	5916	188057	79550184
Neutrophil count decreased	289.30	28.48	142	6005	93817	79644424
Blood bilirubin increased	249.28	28.48	115	6032	66117	79672124
Haemoglobin decreased	207.39	28.48	156	5991	221963	79516278
Pyrexia	170.06	28.48	233	5914	678476	79059765
Hepatocellular carcinoma	168.95	28.48	51	6096	8970	79729271
Product quality issue	88.65	28.48	46	6101	33894	79704347
Hyperbilirubinaemia	72.08	28.48	36	6111	24482	79713759
Influenza like illness	65.80	28.48	50	6097	71657	79666584
Decreased appetite	60.04	28.48	100	6047	342318	79395923
Pruritus	57.21	28.48	106	6041	394542	79343699
Rash	51.09	28.48	127	6020	578231	79160010
Hyperuricaemia	49.04	28.48	22	6125	11777	79726464
Leukopenia	46.70	28.48	51	6096	116462	79621779
Insomnia	46.16	28.48	74	6073	245096	79493145
Malaise	45.80	28.48	110	6037	489759	79248482
Hepatic cirrhosis	45.09	28.48	30	6117	34876	79703365
Hepatitis C	42.55	28.48	20	6127	11905	79726336
Neutropenia	40.02	28.48	76	6071	287634	79450607
Retinopathy	36.31	28.48	13	6134	3878	79734363
Haemolytic anaemia	32.31	28.48	19	6128	17801	79720440
No adverse event	32.05	28.48	25	6122	37167	79701074

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L03AB10	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSTIMULANTS IMMUNOSTIMULANTS Interferons
ATC	L03AB60	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSTIMULANTS IMMUNOSTIMULANTS Interferons
FDA CS	M0025711	Interferon-alpha
FDA EPC	N0000175521	Interferon alpha
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000998	Antiviral Agents
FDA MoA	N0000182137	Cytochrome P450 2D6 Inhibitors
FDA MoA	N0000182138	Cytochrome P450 1A2 Inhibitors
FDA EPC	N0000193883	Antiviral

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Chronic hepatitis C	indication	128302006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Interferon alpha/beta receptor	Membrane receptor	P17181 P48551	INAR1_HUMAN INAR2_HUMAN	AGONIST				DRUG LABEL	DRUG LABEL

External reference:

ID	Source
G8RGG88B68	UNII
4021256	VANDF
C0796545	UMLSCUI
CHEMBL1201561	ChEMBL_ID
DB00022	DRUGBANK_ID
7909	INN_ID
7462	IUPHAR_LIGAND_ID
253453	RXNORM
15887	MMSL
41030	MMSL
d04746	MMSL
008329	NDDF
129477009	SNOMEDCT_US
395823000	SNOMEDCT_US
C417083	MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

None